Cooperative Center for the study of HCV antibody responses and vaccine antigens

HCV抗体反应和疫苗抗原研究合作中心

基本信息

  • 批准号:
    9248879
  • 负责人:
  • 金额:
    $ 91.87万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-04-01 至 2021-03-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): HCV infects nearly 3% of the world population and is often referred as a silent epidemic. It is a leading cause of liver cirrhosis and cancer, and many infected are not aware of the infection until signs of liver malfunction develop. Although significant progress has been made recently in virus treatment, there is no vaccine to stop virus transmission. The central hypothesis for this Program Project is that a vaccine inducing potent broadly neutralizing antibody responses will be effective in preventing HCV transmission in high risk population despite of the virus genetic diversity. Project 1 will study the antibody response in humans who have been vaccinated by the E1E2 antigen in a previous Phase 1 Clinical Trial, and in humans who have been infected by HCV. In parallel, antibody and B cell responses in preclinical animal models vaccinated with E1E2 antigens will be studied and compared to the human studies. This research project will produce a comprehensive set of data on the antibodies, B cell lineages, and HCV immune epitopes to guide rational vaccine design effort. This project will be directed by Dr. Mansun Law. Project 2 will capitalize on the recent structural information on HCV broadly neutralizing epitopes and advances in computational protein design to develop epitope-focused immunogens and their particle forms as vaccine antigens to elicit neutralizing antibody responses to the conserved immune epitopes. This project will be led by Dr. Jiang Zhu. The two projects will utilize antibody and viral reagents developed in the Law lab, which will be managed by an Admin Core. The PIs will also assist each other in their projects with their complementary skills. Dr. Law will provide expertise on HCV, virus neutralizing antibodies, and animal models for immunization. Dr. Zhu will provide expertise in next-generation sequencing of B cell repertoire and immunogen design. The Admin Core will facilitate their communication and productivity by taking care of all administrative duties as well as coordinating research activities including sample organization, shipment and storage between the labs and the collaborative sites. The combined expertise and effort of the team, guided by the valuable advice from internal and external experts, provide a solid foundation to accelerate the discovery of promising HCV vaccine candidates.
 描述(由申请人提供):HCV感染了近3%的世界人口,通常被称为沉默的流行病。它是肝硬化和癌症的主要原因,许多感染者直到出现肝功能障碍的迹象才意识到感染。虽然最近在病毒治疗方面取得了重大进展,但没有疫苗可以阻止病毒传播。本计划项目的中心假设是,尽管存在病毒遗传多样性,但诱导强效广泛中和抗体应答的疫苗将有效预防高危人群中的HCV传播。项目1将研究在先前的I期临床试验中接种E1E2抗原的人和感染HCV的人的抗体应答。同时,将研究接种E1 E2抗原的临床前动物模型中的抗体和B细胞应答,并与人体研究进行比较。该研究项目将产生一套有关抗体、B细胞谱系和HCV免疫表位的全面数据,以指导合理的疫苗设计工作。该项目将由Mansun Law博士指导。项目2将利用最近的结构性 关于HCV广泛中和表位的信息和计算机蛋白质设计的进展,以开发表位聚焦的免疫原及其颗粒形式作为疫苗抗原,以引发对保守免疫表位的中和抗体应答。该项目将由朱江博士领导。这两个项目将利用法律实验室开发的抗体和病毒试剂,由管理核心管理。PI还将以其互补的技能在其项目中相互协助。罗博士将提供关于丙型肝炎病毒,病毒中和抗体和免疫动物模型的专业知识。朱博士将在B细胞库的下一代测序和免疫原设计方面提供专业知识。行政核心将促进他们的沟通和生产力的照顾,以及所有行政职务 作为协调研究活动,包括样品组织,运输和实验室和合作地点之间的存储。在内部和外部专家的宝贵建议指导下,该团队的专业知识和努力为加速发现有前途的HCV候选疫苗提供了坚实的基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mansun Law其他文献

Mansun Law的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mansun Law', 18)}}的其他基金

Broadly Effective HCV Vaccine
广泛有效的 HCV 疫苗
  • 批准号:
    10557871
  • 财政年份:
    2022
  • 资助金额:
    $ 91.87万
  • 项目类别:
Understanding human antibody responses to chronic viral hepatitis C
了解人类抗体对慢性丙型病毒性肝炎的反应
  • 批准号:
    10551237
  • 财政年份:
    2022
  • 资助金额:
    $ 91.87万
  • 项目类别:
Admin Core
管理核心
  • 批准号:
    10557872
  • 财政年份:
    2022
  • 资助金额:
    $ 91.87万
  • 项目类别:
Admin Core
管理核心
  • 批准号:
    10428297
  • 财政年份:
    2022
  • 资助金额:
    $ 91.87万
  • 项目类别:
Broadly Effective HCV Vaccine
广泛有效的 HCV 疫苗
  • 批准号:
    10428296
  • 财政年份:
    2022
  • 资助金额:
    $ 91.87万
  • 项目类别:
Core 001 - Virology Core
核心 001 - 病毒学核心
  • 批准号:
    10428298
  • 财政年份:
    2022
  • 资助金额:
    $ 91.87万
  • 项目类别:
Understanding human antibody responses to chronic viral hepatitis C
了解人类抗体对慢性丙型病毒性肝炎的反应
  • 批准号:
    10435356
  • 财政年份:
    2022
  • 资助金额:
    $ 91.87万
  • 项目类别:
Core 001 - Virology Core
核心 001 - 病毒学核心
  • 批准号:
    10557873
  • 财政年份:
    2022
  • 资助金额:
    $ 91.87万
  • 项目类别:
Rheumatoid factor and cryoglobulinemia in chronic viral infection
慢性病毒感染中的类风湿因子和冷球蛋白血症
  • 批准号:
    9896553
  • 财政年份:
    2019
  • 资助金额:
    $ 91.87万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    9096639
  • 财政年份:
    2016
  • 资助金额:
    $ 91.87万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 91.87万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 91.87万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 91.87万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 91.87万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 91.87万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 91.87万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 91.87万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 91.87万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 91.87万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 91.87万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了